At a glance
ClinicalIndex Comparison RecordPhase 2Not Yet Recruiting· 120 target
Drug / intervention
JMKX000197 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Controlled, Double-Blind, Multi-center Phase II Study to Evaluate JMKX000197 Injection Versus Cisplatin in the Treatment of Malignant Pleural Effusion
In Brief
A Phase 2 clinical trial evaluating JMKX000197 and Cisplatin for Malignant Pleural Effusions (Mpe). Not yet recruiting, targeting 120 participants across 1 site.
Detailed Summary
This study aims to evaluate the efficacy and safety of intrapleural JMKX000197 compared with intrapleural cisplatin in patients with malignant pleural effusion.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMalignant Pleural Effusions (Mpe)
CountriesChina
Collaborators--
Timeline
Phase 2Not Yet Recruiting
20272028
First PostedJun 2026
TodayJul 2026
Enrollment StartAug 2026
Primary CompletionJan 2028
Study CompletionAug 2028
First PostedJun 16, 2026
Enrollment StartAug 17, 2026
Primary CompletionJan 12, 2028
Study CompletionAug 14, 2028
TodayJul 1, 2026
Enrollment to primary: 1.4 yearsPosted 15 days agoPrimary completion in 1.5 years
Arms & Interventions
Arm Aexperimental
JMKX000197
Drug: JMKX000197
Arm Bexperimental
JMKX000197
Drug: JMKX000197
Arm Cactive_comparator
Cisplatin
Drug: Cisplatin
Interventions
JMKX000197drug
Intrapleural administration
Cisplatindrug
Intrapleural administration